An Taoiseach Enda Kenny and the CEO of IDA Ireland Barry O’Leary joined with the chairman and CEO of Jazz Pharmaceuticals Plc Bruce Cozadd today for a ground-breaking ceremony to mark the start of construction on a new manufacturing and development facility for the company in Monksland.
The €50m IDA-supported project is expected to provide 160 jobs during its construction phase, along with a further 50 full-time roles once fully operational.
The 55,000 square foot facility set on a 17-acre site will be completed in 2016.
Speaking at today’s ceremony Enda Kenny said the decision of Jazz Pharmaceuticals to locate locally is “a vote of confidence in our economy and Government policy, like the Action Plan for Jobs, which is targeted towards supporting sectors with the greatest potential to generate jobs”.
“This is a great boost for the local area and the 160 jobs being created in the construction phase will provide an opportunity for some of those people who lost jobs in this sector in recent years,” he added.
Jazz Pharmaceuticals’ Bruce Cozadd added that beginning construction on a manufacturing and development facility in Ireland was a milestone for his company, which is focused on improving patients’ lives by identifying, developing and commercialising products that address unmet medical needs.
“This investment not only strengthens our international manufacturing capabilities, but importantly represents our commitment to expanding our presence in Ireland,” he said.
“We are grateful for the partnership of IDA Ireland and Roscommon County Council who helped make this project possible.”
Meanwhile IDA Ireland’s Barry O’Leary said Jazz Pharmaceuticals’ decision to build a manufacturing site in Ireland is testament to the excellent reputation Ireland has as a global location for biopharmaceutical development and manufacturing.
“This is a strategically important development for Jazz Pharmaceuticals and Ireland is well placed to supoprt manufacturing for the company’s growing commercial portfolio,” he added.